Previous studies have shown that treatment with antibodies to the murine I-A antigen encoded in the major histocompatibility complex attenuates experimental allergic encephalitis and experimental autoimmune myasthenia gravis. These studies were conducted with SJL mice, an inbred strain that is highly susceptible to the induction of these diseases.
Injecting adult mice with monoclonal antibodies against I-A antigen interferes with helper T-cell activation for antibody responses (1) and contributes to the induction of suppressor T cells that reduce delayed-type hypersensitivity responses (2) . In addition, such anti-I-A treatment sharply curtails antibody production to antigens that elicit responses under immune response (Ir) gene control (3) and attenuates two murine autoimmune diseases inducible in SJL mice: experimental autoimmune encephalitis (EAE) and experimental autoimmune myasthenia gravis (EAMG) (4, 5) . These experiments open a new approach to the treatment of human autoimmune disease (6) . However, we describe here severe and prolonged depletions of splenic and lymph-node B cells and impaired antibody responses induced by anti-I-A injections. These findings may limit the universal application of anti-I-A therapy.
Repeated injections of 0.6-1.8 mg/week of monoclonal anti-I-A antibody starting in the neonatal period markedly reduces the number of IgM-bearing B cells in spleens of mice up to age 7 weeks (7). Here we show that even a single injection of 4 mg of monoclonal anti-I-A antibody into an adult SJL/J mouse is sufficient to virtually eliminate B cells within 5 days and that subsequent recovery is slow. Complex effects on antibody responses are also presented below.
B cells were recently subdivided into three major subpopulations based on correlated IgM and IgD levels, using multiparameter measurements made with a fluorescence activated cell sorter (FACS) (8, 9 ). Here we have followed the Bcell depletion and recovery phases induced by anti-I-A treatment by similar FACS subpopulation analyses in SJL and in a second strain, C3H.Ighb (CKB). CKB cells provided the immunogen for generating the 10-3.6 hybridoma, which makes the anti-I-A used in these studies. It also has the same immunoglobulin allotype as SJL but does not have the immunologic abnormalities seen in SJL (10, 11) .
MATERIALS AND METHODS Animals. Young adult SJL/J mice were obtained from our colony, and CKB (C3H.Ighb) mice were provided by H. McDevitt.
Monoclonal Antibodies. The anti-I-A antibody was from the hybridoma 10-3.6. It recognizes the public specificity Ia.17 associated with H-2kr'sf and is Igh-lb allotype (12) . It was used as ascites fluid or purified by ammonium sulfate precipitation and acid elution from staphylococcal protein ASepharose. Rat anti-mouse IgM (13), mouse anti-mouse Igh5b (IgD b allotype) (14) and mouse anti-Igh-lb (IgG2a) (15) were purified and fluorochrome-coupled as described (16) . Two-Color Immunofluorescence Analyses. Preparation of cells, staining procedures, and data collection procedures were as described (16) . Large-angle scatter (near 90 degrees) was used to assess cell granularity. Cells falling within the macrophage range of large-angle scatter were not examined in our analyses. Two-color staining data are presented as "contour plots" (Figs. 1 and 2 ) that are representations of three-dimensional surfaces in which the levels of green and red fluorescence per cell define locations on a two-dimensional surface, and the frequency of cells with that value of Abbreviations: EAE, experimental autoimmune encephalitis; EAMG, experimental autoimmune myasthenia gravis; FACS, fluorescence-activated cell sorter; KLH, keyhole limpet hemocyanin; CGG, chicken gamma globulin; DNP, 2,4 dinitrophenyl hapten; Ir, immune response.
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RESULTS AND DISCUSSION
CKB and SJL mice show fairly similar splenic IgM/IgD subpopulation distributions-i.e., the predominant B-cell subpopulation (I) tends to be equivalent in frequency in the two strains, whereas the other splenic subpopulations (II and III) tend to be somewhat larger in CKB ( (Figs. 2 and 3 ). Recovery began shortly thereafter; however, although the splenic B-cell frequency rose to roughly normal levels within the next 3 weeks (by day 33), the predominant B-cell population in adult mice (labeled I in Fig. 1 ) was still well below its normal frequency. This population, which normally appears late in B-cell ontogeny (8) , was also the last to reappear in the treated mice. Thus, 33 days after anti-I-A injection, population I contained roughly 20% of the spleen cells rather than the usual 30% of spleen cells found in untreated animals. CKB mice show a similar but somewhat lower sensitivity (Table 2) . Furthermore, although we routinely injected 4 mg of anti-I-A, 1/10th that amount (0.4 mg) was still sufficient to reduce splenic B-cell frequencies by about 50% on day 5 (Table 2) . Thus, the failure to completely eliminate B cells is not due to treatment with inadequate amounts of anti-I-A antibody.
Similarly, the long-term perturbation of B cell subpopulations (see Fig. 3 ) in anti-I-A-treated mice does not depend upon long-term persistence of injected antibody. That is, although anti-I-A levels in serum rose immediately after a single 4-mg injection of anti-I-A and were still above 1 mg/ml 17 hr later, they dropped during the next 2 days to about 0.01 mg/ml on day 3 and to less than 0.2 ,ug/ml by day 7.
The effects of anti-I-A treatment on antibody responses persist even longer than noticeable effects on B-cell frequencies. We followed the protocol used in earlier work demonstrating that anti-I-A treatment impairs Ir gene-controlled antibody responses to the synthetic polypeptide (H,G)-A-L (3). To develop a more general view of the effect of anti-I-A treatment on antibody responses, we immunized with typical hapten-carrier conjugates (responses to which are not under differential Ir gene control) and measured individual IgG isotype responses to the hapten and carrier after each immunization. Thus, we injected SJL mice with anti-I-A on the day Data from these studies show clearly that anti-I-A treatment results in the selective, long-term impairment of components of the antibody response to priming antigens presented 1 day after the first anti-I-A injection (Tables 3 and 4) . Virtually all treated animals showed reductions in primary, secondary, and tertiary responses; however, by and large, primary responses tended to be more impaired than secondary and tertiary responses, IgG1 responses tended to be more impaired than IgG2a and IgG2b responses, and anticarrier responses tended to be more impaired than anti-hapten responses. Surprisingly, IgG2a and IgG2b anti-hapten responses in most of the treated animals reached essentially normal secondary levels after the second immunization, despite severe B-cell deficiencies in the immunized animals at the time they were restimulated (Tables 3 and 4) .
In the third immunization in this series, the antigen (DNP-CGG) was introduced 8 weeks after the last anti-I-A injection. These animals no longer had detectable amounts of anti-I-A in circulation (data not shown) and had regained normal numbers of B cells (Fig. 3) . Nevertheless, their IgG1 anti-DNP responses were significantly below the tertiary response level in control animals (see Table 3 ). The IgG1 responses to DNP-CGG in treated animals were somewhat Immunology: Waldor et al. In essence, the findings we have presented suggest two potential mechanisms for explaining the effectiveness of anti-I-A injection in the immunosuppression and disease attenuation studies (3) (4) (5) . First, the high serum anti-I-A levels generated by repeated anti-I-A injections may interfere with I-A-dependent antigen presentation or other regulatory interactions necessary for antibody production. Secondly, the rapid disappearance of B cells may deplete "virgin" precursors capable of giving rise to IgG antibody-forming cells and memory B cells needed for secondary responses. Both of these mechanisms are consistent with the available response data and both, in fact, probably exert important influences on antibody production in the anti-I-A-treated animal.
Our previous studies suggest that these influences may be mediated by an epitope-specific system (18) that independently regulates isotype antibody responses to individual epitopes on antigenic molecules. Studies with this system indicate that antigenic priming while B cell development or function is impaired results in the induction of a specific, persistent, T cell-mediated suppression of antibody production (18) . However, the suppression generated in these "carrier/hapten-carrier" immunization studies tends to affect IgG2a and IgG2b antibody responses more than IgG1 responses (18) and, thus, differs from the impairment found in anti-I-A-treated animals.
The studies we have presented indicate that caution is needed before using the promising anti-Ia therapy for human autoimmune disease. In summary we have shown that (t) B cells are severely depleted by anti-I-A treatment; (it) recovery of the B cells in treated animals lags considerably behind the disappearance of the injected antibody; (iii) genetic differences significantly influence sensitivity to B-cell depletion and recovery after anti-I-A treatment; (iv) introducing antigens while B cells are depleted and while I-A antigen on cells is potentially blocked by circulating anti-I-A markedly interferes with all immediate and some long-term responses to the antigens; and (v) some isotype components of antibody responses are more affected than others. Thus, combining these points with the general caution expressed previously (6), we suggest that anti-Ia therapy in humans should not be considered exempt from possible untoward consequences.
